Company attributes
Other attributes
Pearl Therapeutics is a biotechnology company developing therapies for respiratory diseases that is headquartered in Morristown, New Jersey and was founded in 2006 Sarvajna Dwivedi.
On June 10, 2013 AstraZeneca announced they will be entering into a definitive merger agreement with Pearl Therapeutics. AstraZeneca purchased 100% of Pearl Therapeutics shares for up to $1.15 billion.
On October 19, 2010 Pearl Therapeutics completed their series C funding round with $69 million in funding from Vatera Healthcare Partners (lead investor), New Leaf Venture Partners, and 5AM Ventures.
On October 1, 2012 Pearl Therapeutics completed a private equity fundraising round with $23.3 million in funding from Vatera Healthcare Partners, New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
On November 13, 2012 Pearl Therapeutics completed their series D funding round with $65 million in funding from Vetera Healthcare Partners (lead investor), New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
On April 1, 2013 Pearl Therapeutics completed a venture funding round with $41.7 million in funding from Vatera Healthcare Partners (lead investor), New Leaf Venture Partners, Clarus Ventures, and 5AM Ventures.
